Literature DB >> 16924046

Facial resurfacing for nonmelanoma skin cancer prophylaxis.

Basil M Hantash1, Daniel B Stewart, Zachary A Cooper, Wingfield E Rehmus, R James Koch, Susan M Swetter.   

Abstract

OBJECTIVE: To determine the effect of facial skin resurfacing for treatment of actinic keratoses (AKs) and prophylaxis against new primary basal and squamous cell carcinomas in individuals with previous nonmelanoma skin cancer (NMSC) or severe photodamage.
DESIGN: Randomized, prospective 5-year trial.
SETTING: Dermatology and otolaryngology clinics of a Veterans Affairs hospital. PATIENTS: Thirty-four patients with a history of facial or scalp AKs or basal or squamous cell carcinoma were enrolled. Five of 7 eligible patients who declined study-related treatment were used as controls. Twenty-seven patients were randomized to 3 treatment arms; 3 patients were discontinued from the study.
INTERVENTIONS: Carbon dioxide laser resurfacing, 30% trichloroacetic acid peel, or 5% fluorouracil cream applied twice daily for 3 weeks. MAIN OUTCOME MEASURES: Reduction in the number of AKs was measured 3 months after treatment. The incidence of new NMSC in treated areas was assessed between January 1, 2001, and June 30, 2005. Times from baseline to diagnosis of first skin cancer were compared between the treatment and control groups.
RESULTS: Treatment with fluorouracil, trichloroacetic acid, or carbon dioxide laser resulted in an 83% to 92% reduction in AKs (P< or =.03), a lower incidence of NMSC compared with the control group (P<.001), and a trend toward longer time to development of new skin cancer compared with the control group (P=.07). However, no significant differences were noted among the treatment groups.
CONCLUSION: All 3 modalities demonstrated benefit for AK reduction and skin cancer prophylaxis compared with controls and warrant further study in a larger trial.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924046     DOI: 10.1001/archderm.142.8.976

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  13 in total

1.  Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.

Authors:  Joel L Cohen
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

2.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

3.  Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses.

Authors:  Brooke Fidler; Tamara Goldberg
Journal:  P T       Date:  2014-01

Review 4.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  Single Ablative Fractional Resurfacing Laser Treatment For Forearm Actinic Keratoses: 6-Month Follow-Up Data From An Intrapatient Comparison Between Treated and Untreated Sites.

Authors:  Roy Chen; Jeffrey J Wargo; Amy Williams; Elizabeth Cates; Dan F Spandau; Christina Knisely; Jeffrey B Travers
Journal:  Lasers Surg Med       Date:  2019-11-17       Impact factor: 4.025

6.  Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.

Authors:  Brian Berman; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Daniel M Siegel
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

Review 7.  [Skin tumours of the facial area].

Authors:  M Braun-Falco
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

Review 8.  Vitamin D and Vitamin D Analogs as Adjuncts to Field Therapy Treatments for Actinic Keratoses: Current Research and Future Approaches.

Authors:  Zafer Sattouf; Steven J Repas; Jeffrey B Travers; Craig A Rohan
Journal:  J Skin Cancer       Date:  2021-06-19

9.  Reversing the aging stromal phenotype prevents carcinoma initiation.

Authors:  Davina A Lewis; Jeffrey B Travers; Christiane Machado; Ally-Khan Somani; Dan F Spandau
Journal:  Aging (Albany NY)       Date:  2011-04       Impact factor: 5.682

Review 10.  Optimal treatment of actinic keratoses.

Authors:  Elizabeth E Uhlenhake
Journal:  Clin Interv Aging       Date:  2013-01-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.